Development and Validation of a Stability-Indicating Liquid Chromatographic Method with Mass-Spectrometric Detection for the Analysis of Apixaban and Determination of Production Related Impurities

Apixaban is a novel anticoagulant drug acting as a direct, selective and reversible inhibitor of coagulation factor Xa. The purpose of this work was to develop and validate a sensitive, stability-indicating LC-MS method for the analysis of apixaban and estimation of production-related substances in the active pharmaceutical ingredient (API) and pharmaceutical dosage forms. The analyses were carried out on a Macherey-Nagel Nucleodur C18 column (250 × 4.6 mm, 5 μm particle size) with a mobile phase containing acetonitrile and water in gradient program at a flow rate of 0.8 mL/min, the column oven temperature 25°C, and the UV detection tuned to 270 nm. Apixaban was subjected to stress conditions of oxidative, acid, base, hydrolytic, thermal and photolytic degradation, and found susceptible to acid and base hydrolysis conditions, while it was stable under thermal, photolytic, and oxidative degradation conditions. The degradation products were well resolved from the main peak and its impurities, proving the stability-indicating power of the proposed method. The proposed method was validated as per International Conference on Harmonization (ICH) guidelines. The method is suitable for practical routine analysis and it has been successfully applied to analyze apixaban in eliquis brand preparations. All analytical results were acceptable according to the pharmaceutical requirements.

This is a preview of subscription content, access via your institution.

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.

References

  1. 1.

    Eliquis (Apixaban), Bristol Meyers Squibb Co. & Pfizer Inc. (2015).

  2. 2.

    Eliquis (Apixaban), US Food and Drug Administration (2015).

  3. 3.

    R. Agrawal, P. Jain, and S. N. Dikshit, Curr. Drug Targets, 13, 863 – 875 (2012).

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    P. Wong, E. Crain, B. Xin, et al., J. Thromb. Hemost., 6, 820 – 829 (2008).

    CAS  Article  Google Scholar 

  5. 5.

    ICH Guidelines Q3A (R2), Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland (2006).

  6. 6.

    S. Görög, Trends Anal. Chem., 25, 755 – 757 (2006).

    Article  CAS  Google Scholar 

  7. 7.

    H. K. Vatsa. S. Gottapu, and B. Anitha, Asian J. Med. Pharm. Sci., 3, 210 – 213 (2015).

    Google Scholar 

  8. 8.

    S. B. Landge, S. A. Jadhav, S. B. Dahale, et al., Am. J. Anal. Chem., 6, 539 (2015).

    CAS  Article  Google Scholar 

  9. 9.

    E. Schmitz, K. Boonen, D. den Heuvel, et al., J. Thromb. Hemost., 12, 1636 – 1646 (2014).

    CAS  Article  Google Scholar 

  10. 10.

    X. Delavenne, P. Mismetti, and T. Basset, J. Pharm. Biomed. Anal., 78, 150 – 153 (2013).

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    S. S. Prabhune, R. S. Jaguste, P. L. Kondalkar, et al., Sci. Pharm., 82, 777 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    European Pharmacopoeia, 7th Edition (2010).

  13. 13.

    United States Pharmacopeia – National Formulary, USP 38-NF, Rockville, USA (2015).

  14. 14.

    British Pharmacopoeia, British Pharmacopoeia Commission, London (2017).

  15. 15.

    ICH Guidelines Q2 (R1), Validation of Analytical Procedures, Text and Methodology, Geneva, Switzerland (2005).

Download references

Acknowledgements

The authors are thankful to colleagues in the central laboratory at the Faculty of Science for their cooperation in carrying out this work. The authors would like to thank Dr. Heba Ghazal for her help in funding the project.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Basima Arous.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Arous, B., Al-Mardini, M.A. Development and Validation of a Stability-Indicating Liquid Chromatographic Method with Mass-Spectrometric Detection for the Analysis of Apixaban and Determination of Production Related Impurities. Pharm Chem J 52, 573–581 (2018). https://doi.org/10.1007/s11094-018-1862-x

Download citation

Keywords

  • apixaban
  • impurities
  • stability-indicating method, LC-MS, validation